MedTrace Logo

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

NCT06305351 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-11-01

No results posted yet for this study

Summary

This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)

Conditions

  • Obesity
  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

K-757 and K-833 QD

Both administered orally once daily

DRUG

K-757 and K-833 BID

Both administered orally twice daily

DRUG

Matching placebo to K-757 and K-833 QD

Both administered orally once daily

DRUG

Matching placebo to K-757 and K-833 BID

Both administered orally twice daily

Sponsors & Collaborators

  • Kallyope Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-07
Primary Completion
2024-05-15
Completion
2024-06-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06305351 on ClinicalTrials.gov